Navigation Links
Helix BioPharma Announces Q2 2009 Financial Results
Date:3/16/2009

AURORA, Ontario, March 16 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second quarter of fiscal 2009, ended January 31, 2009.

RECENT HIGHLIGHTS

  • Helix filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission which became effective on March 12, 2009

  • Helix received regulatory approval to commence a small European Phase II pharmacokinetic study in human subjects prior to initiating its planned Phase IIb/III trials

  • Dr. Chao presented L-DOS47's mechanism of action at the Second Conference of Lung Cancer in Warsaw, Poland.

Results from Operations

Three and six month periods ended January 31, 2009 compared to the same periods in the previous year

Loss for the period

The Company recorded a loss of $4,252,000 and $6,573,000, respectively, for the three and six month periods ended January 31, 2009, for a loss per common share of $0.08 and $0.13, respectively. In the comparative three and six month periods ended January 31, 2008, the Company recorded a loss of $1,526,000 and $3,170,000, respectively, for a loss per common share of $0.04 and $0.08, respectively.

Revenues

Total revenues for the three month period ended January 31, 2009 totaled $863,000 (2008 - $791,000), resulting in an increase of $72,000 or 9.1%. Total revenues, for the six month period ended January 31, 2009 totaled $1,982,000 (2008 - $1,676,000), resulting in an increase of $306,000 or 18.3%.

Product Revenue

Product revenue totaled $740,000 and $1,661,000 respectively for the three and six month periods ended January 31, 2009 and represent an increase of $88,000 (13.5%
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Selexis SA , a ... discovery and mammalian cell line development, announced today new ... will be presented at the 10th Annual Cell ... 8 – 10, 2014 at the Double Tree by ... following abstract will be presented during an oral presentation: ...
(Date:7/30/2014)... Albany, NewYork (PRWEB) July 30, 2014 ... population, the increase of personal health expenditure as ... government health care system, China diagnostic reagent industry ... reagents occupy over 90%. In 2013, Chinese in ... which RMB16.61 billion came from in vitro diagnostic ...
(Date:7/30/2014)... Vycom announces the addition of Thermax ... meet Factory Mutual (FM) 4910 fire propagation and smoke ... benches, process tools, fume hoods, furniture and cabinetry. These ... semiconductor wafers used in electronic chip manufacturing. , ... with excellent workability and superior aesthetics. It is available ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4
... Pinnacle Biologics, a,private, full-service pharmaceutical and biotech ... agreement with pharmexx to expand sales,support activities in ... of the,agreement were not disclosed., Viren Grover, ... to conclude this agreement with pharmexx, which allows ...
... ON, July 9 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and six months ended May 31, 2008. All dollar ... At May 31, 2008, our cash and cash ... 29, 2008., The net loss for the second ...
... Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ABBOTT PARK, ... V(TM) USA post-approval study, with six,hospital centers already recruiting and enrolling ... the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The XIENCE V USA ...
Cached Biology Technology:Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2Vasogen Announces Second Quarter 2008 Results 2Vasogen Announces Second Quarter 2008 Results 3Vasogen Announces Second Quarter 2008 Results 4Vasogen Announces Second Quarter 2008 Results 5Vasogen Announces Second Quarter 2008 Results 6Vasogen Announces Second Quarter 2008 Results 7Vasogen Announces Second Quarter 2008 Results 8Vasogen Announces Second Quarter 2008 Results 9Vasogen Announces Second Quarter 2008 Results 10Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/29/2014)... academics in the University of Bristol,s Nutrition and Behaviour ... calories into account when planning meals. , The research, ... of Ingestive Behavior Conference (SSIB 2014) in Seattle, USA ... we do. , The team was led by Professor ... Experimental Psychology. , As part of a Biotechnology and ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... BETHESDA, MD August 23, 2007 On August 16, the ... blood-thinner warfarin, sold under the brand name Coumadin. The new ... that may be safer for patients with variations in two ... through genetic testing, which may be a useful tool in ...
... Optics 2007 (FiO), the 91st Annual Meeting of the ... 16-20 in San Jose, Calif., alongside Laser Science XXIII, ... of Laser Science. Reporters interested in obtaining a ... at 202.416.1437, cmorri@osa.org . FiO RESEARCH ...
... system designed for brain tumor therapy has shown promising ... devised by University of Nottingham scientists. The project, conducted ... Human Development, will be featured in the September issue ... cancers is particularly difficult for a number of reasons, ...
Cached Biology News:American College of Medical Genetics responds to new FDA labeling decision for warfarin 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Novel 3-D cell culture model shows selective tumor uptake of nanoparticles 2
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... The standard of the Axima range, ... high mass accuracy, resolution, sensitivity and ... with both linear and reflectron time-of-flight ... reflectron enables the generation of seamless ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: